QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:TALS

Talaris Therapeutics (TALS) Stock Forecast, Price & News

$2.85
-0.02 (-0.70%)
(As of 09/28/2023 ET)
Compare
Today's Range
$2.83
$2.92
50-Day Range
$2.68
$3.08
52-Week Range
$0.89
$3.29
Volume
67,276 shs
Average Volume
400,359 shs
Market Capitalization
$121.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

Talaris Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
163.2% Upside
$7.50 Price Target
Short Interest
Healthy
2.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Talaris Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

668th out of 969 stocks

Biological Products, Except Diagnostic Industry

106th out of 161 stocks


TALS stock logo

About Talaris Therapeutics (NASDAQ:TALS) Stock

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.

TALS Price History

TALS Stock News Headlines

Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, NEX, CIR
Tourmaline, Talaris Announce All-stock Merger
See More Headlines
Receive TALS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TALS Company Calendar

Last Earnings
8/14/2023
Today
9/28/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TALS
Fax
N/A
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.50
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+163.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-73,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.33 per share

Miscellaneous

Free Float
35,708,000
Market Cap
$121.87 million
Optionable
Not Optionable
Beta
2.26
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Ms. Mary Kay Fenton (Age 59)
    Interim CEO, Pres, CFO & Treasurer
    Comp: $598.98k
  • Dr. Suzanne T. Ildstad M.D. (Age 70)
    Founder, Member of Scientific Advisory Board, Sr. Scientific Advisor & Director
    Comp: $318.3k
  • Ms. Suzanne Tollerud
    VP of Corp. Devel.













TALS Stock - Frequently Asked Questions

Should I buy or sell Talaris Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Talaris Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TALS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TALS, but not buy additional shares or sell existing shares.
View TALS analyst ratings
or view top-rated stocks.

What is Talaris Therapeutics' stock price forecast for 2023?

2 brokerages have issued 1 year price targets for Talaris Therapeutics' shares. Their TALS share price forecasts range from $3.00 to $12.00. On average, they expect the company's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 163.2% from the stock's current price.
View analysts price targets for TALS
or view top-rated stocks among Wall Street analysts.

How have TALS shares performed in 2023?

Talaris Therapeutics' stock was trading at $1.02 on January 1st, 2023. Since then, TALS shares have increased by 179.4% and is now trading at $2.85.
View the best growth stocks for 2023 here
.

Are investors shorting Talaris Therapeutics?

Talaris Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 593,800 shares, an increase of 24.1% from the August 31st total of 478,500 shares. Based on an average daily trading volume, of 308,800 shares, the days-to-cover ratio is currently 1.9 days. Currently, 2.8% of the company's stock are sold short.
View Talaris Therapeutics' Short Interest
.

When is Talaris Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our TALS earnings forecast
.

How were Talaris Therapeutics' earnings last quarter?

Talaris Therapeutics, Inc. (NASDAQ:TALS) posted its earnings results on Monday, August, 14th. The company reported ($0.20) earnings per share for the quarter.

When did Talaris Therapeutics IPO?

(TALS) raised $150 million in an initial public offering (IPO) on Friday, May 7th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO.

What is Talaris Therapeutics' stock symbol?

Talaris Therapeutics trades on the NASDAQ under the ticker symbol "TALS."

Who are Talaris Therapeutics' major shareholders?

Talaris Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (5.55%), BML Capital Management LLC (4.76%), Great Point Partners LLC (1.59%), JPMorgan Chase & Co. (1.08%), Renaissance Technologies LLC (1.05%) and Walleye Capital LLC (0.73%). Insiders that own company stock include Francois Nader, Longitude Capital Partners Iii, Sandip Agarwala, Scott Requadt and Suzanne Ildstad.
View institutional ownership trends
.

How do I buy shares of Talaris Therapeutics?

Shares of TALS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Talaris Therapeutics' stock price today?

One share of TALS stock can currently be purchased for approximately $2.85.

How much money does Talaris Therapeutics make?

Talaris Therapeutics (NASDAQ:TALS) has a market capitalization of $121.87 million. The company earns $-73,890,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis.

How can I contact Talaris Therapeutics?

The official website for the company is talaristx.com. The company can be reached via phone at 502-398-9250.

This page (NASDAQ:TALS) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -